Neuroendocrine cancer pertinent cancer susceptibility

Gene: RET

Green List (high evidence)

RET (ret proto-oncogene)
EnsemblGeneIds (GRCh38): ENSG00000165731
EnsemblGeneIds (GRCh37): ENSG00000165731
OMIM: 164761, Gene2Phenotype
RET is in 28 panels

2 reviews

Ellen McDonagh (Genomics England Curator)

Comment on list classification: Details checked against the original gene list from Clare Turnbull.
Created: 26 Jul 2017, 12:56 p.m.

Clare Turnbull (Queen Mary University London)

Green List (high evidence)

Phenotypes
Neuroendocrine cancer

History Filter Activity

7 Sep 2018, Gel status: 3

Panel promoted to version 1.0

Louise Daugherty (Genomics England Curator)

Ellen McDonagh: Comment on list classification

26 Jul 2017, Gel status: 4

Set mode of pathogenicity

Ellen McDonagh (Genomics England Curator)

Mode of pathogenicity for RET was changed to Loss-of-function variants (as defined in pop up message) DO NOT cause this phenotype - please provide details in the comments

26 Jul 2017, Gel status: 4

Set Mode of Inheritance

Ellen McDonagh (Genomics England Curator)

Mode of inheritance for RET was changed to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted

26 Jul 2017, Gel status: 4

Gene classified by Genomics England curator

Ellen McDonagh (Genomics England Curator)

This gene has been classified as Green List (High Evidence).

19 Jul 2017, Gel status: 0

Added New Source

Ellen McDonagh (Genomics England Curator)

RET was added to Neuroendocrine cancerpanel. Sources: Expert list

19 Jul 2017, Gel status: 0

Created

Ellen McDonagh (Genomics England Curator)

RET was created by ellenmcdonagh